Q-omics provides the consensus-scored FCRL6 profile across patient tissues and cancer cell-line models. FCRL6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FCRL6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FCRL6 RNA expression shows 17,099 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where FCRL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCRL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCRL6 survival associations across molecular data types. FCRL6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCRL6 RNA expression–survival associations across cancer types. High FCRL6 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, UCEC, LUAD and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FCRL6 RNA expression.
This table summarizes FCRL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FCRL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCRL6 shows lower tumor expression in LUSC, LUAD, BRCA and UCEC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher FCRL6 RNA expression in tumor versus normal tissue (log2 FC = +1.491, t-test p < 0.001).
This table shows molecular features associated with FCRL6 in patient tissues and cancer cell lines. In patient samples, FCRL6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FCRL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
